Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2016 October;64(5) > Minerva Cardioangiologica 2016 October;64(5):542-51

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as

 

REVIEWS   

Minerva Cardioangiologica 2016 October;64(5):542-51

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Current knowledge and future perspectives regarding stented valves

Giuseppe SANTARPINO, Jurij M. KALISNIK, Theodor FISCHLEIN, Steffen PFEIFFER

Department of Cardiac Surgery, Klinikum Nürnberg, Paracelsus Medical University, Nuremberg, Germany


PDF


Aortic valve bioprostheses are commonly implanted in the current era (also in younger patients) as they may obviate the need for anticoagulation while providing better hemodynamic performance and a more favorable quality of life. The steady increase in the use of biological valves has prompted the development of several different models of conventional stented bioprostheses. At present, there are four main types of stented aortic bioprostheses that compete in the market: the LivaNova Crown PRT (LivaNova Group, Burnaby, Canada), the St. Jude Medical Trifecta (St. Jude Medical, St. Paul, MN, USA), the Carpentier-Edwards Perimount Magna Ease (Edwards Lifesciences, Irvine, CA, USA), and the Medtronic Mosaic Ultra (Medtronic, Inc., Minneapolis, MN, USA). The purpose of this review is to describe the features of these bioprosthetic valve models and to compare the data provided by the manufacturers with those derived from the available literature.

top of page